Oncogene Cancer Research shared a post on LinkedIn:
“For years, treatment for ALK+ lung cancer has focused on inhibiting the driver. What if we could degrade it instead?
A new approach is emerging. TRI-611, a molecular glue degrader, has received FDA Fast Track designation – and the first patient has now been dosed in its phase 1/2 trial.
Unlike traditional ALK inhibitors, TRI-611 is designed to eliminate the ALK fusion protein altogether, tagging it for destruction rather than simply blocking its activity. Resistance to ALK TKIs remains a major challenge. A therapy that can degrade the target protein could offer a new way to overcome that resistance.
Encouraging to see this trial now moving forward globally, including in the UK.
A different mechanism. A new possibility for people living with ALK+ lung cancer.”
Other articles about lung cancer on OncoDaily.